Adjunct immunotherapy with Ag85 complex proteins based subunit vaccine in a murine model of Mycobacterium tuberculosis infection

Immunotherapy

Volumn 1, Issue 1, 2009, Pages 31-37

  Giri, Pramod K ^b   Verma, Indu ^a   Khuller, Gopal K ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^b UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

Ag85 complex proteins; Antituberculous drugs; Immunotherapy; Mycobacterium tuberculosis

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; DIMETHYLDIOCTADECYLAMMONIUM BROMIDE; HERMES ANTIGEN; INTERLEUKIN 4; ISONIAZID; MYCOBACTERIUM ANTIGEN; RIFAMPICIN;

ACTIVE IMMUNIZATION; ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; LUNG; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SPLEEN; T LYMPHOCYTE ACTIVATION; TUBERCULOSIS;

ACYLTRANSFERASES; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL LOAD; BACTERIAL PROTEINS; BACTERIAL VACCINES; CELLS, CULTURED; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-4; LUNG; MICE; MICE, INBRED BALB C; MODELS, ANIMAL; MYCOBACTERIUM TUBERCULOSIS; OLIGODEOXYRIBONUCLEOTIDES; QUATERNARY AMMONIUM COMPOUNDS; SPLEEN; T-LYMPHOCYTES; TUBERCULOSIS, PULMONARY;

EID: 70449422248     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/1750743X.1.1.31     Document Type: Article

References (27)

1. World Health Organization: Global tuberculosis control: surveillance, planning financing. WHO/HTM/TB/2005. WHO Report. Geneva, Switzerland (2005).
2. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC: Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. JAMA 282(7), 677-686 (1999). (Pubitemid 29384157)
3. Kaufmann SHE: Is the development of a new tuberculosis vaccine possible? Nat. Med. 6(1), 955-960 (2000).
4. Tomioka H: Adjunctive immunotherapy of mycobacterial infections. Curr. Pharm. Des. 10(26), 3297-3312 (2004).
5. Zhu D, Jiang S, Luo X: Therapeutic effects of Ag85B and MPT64 DNA vaccines in a murine model of Mycobacterium tuberculosis infection. Vaccine 23(37), 4619-4624 (2005). (Pubitemid 41033377)
6. Ha SJ, Jeon BY, Youn JI, Kim SC, Cho SN, Sung YC: Protective effect of DNA vaccine during chemotherapy on reactivation and reinfection of Mycobacterium tuberculosis. Gene Ther. 12(7), 634-638. (2005).
7. Juffermans NP, Leemans JC, Florquin S et al.: CpG oligodeoxynucleotides enhance host defense during murine tuberculosis. Infect. Immun. 70(1), 147-1152 (2002).
8. Fonseca DM, Silva CL, Paula MO et al.: Increased levels of interferon-γ primed by culture filtrate proteins antigen and CpG-ODN immunization do not confer significant protection against Mycobacterium tuberculosis infection. Immunology 12(4), 508-517 (2007).
9. Hsieh MJ, Junqueira-Kipnis AP, Hoeffer A, Turner OC, Orme IM: Incorporation of CpG oligodeoxynucleotide fails to enhance the protective efficacy of a subunit vaccine against Mycobacterium tuberculosis. Vaccine 22(5-6), 655-659 (2004). (Pubitemid 38114895)
10. Subrahmanyam D: Studies on the poly glycerophosphatides of Mycobacterium tuberculosis. Can. J. Biochem. 42(1), 1192-1201 (1964).
11. Giri PK, Verma I, Khuller GK: Enhanced immunoprotective potential of Mycobacterium tuberculosis Ag85 complex protein based vaccine against airway Mycobacterium tuberculosis challenge following intranasal administration. FEMS Immunol. Med. Microbiol. 47(2), 233-241 (2006).
12. Brandt L, Elhay M, Rosenkrands I, Lindblad EB, Andersen P: ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect. Immun. 68(2), 791-795 (2000).
13. Kalita A, Verma I, Khuller GK: Role of human neutrophil peptide-1 as a possible adjunct to antituberculosis chemotherapy. J. Infect. Dis. 190(8), 1476-1480 (2004).
14. Silva CL, Bonato VL, Coelho-Castelo AA, et al.: Immunotherapy with plasmid DNA encoding mycobacterial Hsp65 in association with chemotherapy is a more rapid and efficient form of treatment for tuberculosis in mice. Gene Ther. 12(3), 281-287 (2005).
15. Lowrie DB, Tascon RE, Bonato VL et al.: Therapy of tuberculosis in mice by DNA vaccination. Nature 400(6741), 269-271 (1999).
16. Taylor JL, Turner OC, Basaraba RJ, Belisle JT, Huygen K, Orme IM: Pulmonary necrosis resulting from DNA vaccination against tuberculosis. Infect. Immun. 71(4), 2192-2198 (2003).
17. Turner J, Rhoades ER, Keen M, Belisle JT, Frank AA, Orme IM: Effective preexposure tuberculosis vaccines fail to protect when they are given in an immunotherapeutic mode. Infect. Immun. 68(3), 1706-1709 (2000).
18. Silva CL, Lowrie DB: Identification and characterization of murine cytotoxic T cells that kill Mycobacterium tuberculosis. Infect. Immun. 68(6), 3269-3274 (2000).
19. Collins HL, Kaufmann SHE: The many faces of host responses to tuberculosis. Immunology 103(1), 1-9 (2001).
20. Flynn JL, Ernst JD: Immune responses in tuberculosis. Curr. Opin. Immunol. 12(1), 432-438 (2000).
21. Bonato VL, Lima VM, Tascon RE, Lowrie DB, Silva CL: Identification and characterization of protective T cells in HSP65 DNA-vaccinated and Mycobacterium tuberculosis-infected mice. Infect. Immun. 66(1), 169-175 (1998).
22. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR: An essential role for interferon γ in resistance to Mycobacterium tuberculosis. J. Exp. Med. 178(6), 2249-2254 (1993).
23. Goonetilleke NP, McShane H, Hannan CM, Anderson RJ, Brookes RH, Hill, AV: Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J. Immunol. 171(3), 1602-1609 (2003). (Pubitemid 36900097)
24. Cardona PJ, Amat I, Gordillo S et al.: Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis. Vaccine 23(11), 1393-1398 (2005). (Pubitemid 40127332)
25. Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A: Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401(6754), 708-712 (1999). (Pubitemid 129515761)
26. Abbas AK, Murphy KM, Sher A: Functional diversity of helper T lymphocytes. Nature 383(6603), 787-793 (1996).
27. Lazanvecchia A: Identifying strategies for immune intervention. Science 260(5110), 937-944 (1993).